The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation
Publication: Journal of Comparative Effectiveness Research
Abstract
Unless contraindicated, anticoagulant therapy should be prescribed to elderly patients with atrial fibrillation. Direct-acting oral anticoagulants (DOACs) are superior to vitamin K antagonists for preventing stroke. This, together with their higher net clinical benefit, makes DOACs the treatment of choice in this population. However, due to the concerns about bleeding and the need for dose adjustment based on clinical variables, underdosing of DOACs is common and the risk of stroke high. Drugs with more easily adjusted doses are likely associated with a lower risk of dosing errors and, therefore, a greater protective effect. Correct dosing can ensure a maximal net benefit of DOACs in elderly patients with atrial fibrillation.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370–2375 (2001).
2.
Suárez Fernández C, Camafort M, Cepeda Rodrigo JM et al. Tratamiento antitrombótico en el paciente anciano con fibrilación auricular. Rev. Clin. Esp. 215, 171–181 (2015).
3.
Monteiro P. The SAFIRA study: a reflection on the prevalence and treatment patterns of atrial fibrillation and cardiovascular risk factors in 7500 elderly subjects. Rev. Port. Cardiol. 37(4), 307–313 (2018).
4.
Suárez Fernández C, Mostaza JM, Castilla Guerra L et al. Seguimiento de las recomendaciones del Informe de Posicionamiento Terapéutico sobre el tratamiento con anticoagulantes orales en pacientes ancianos con fibrilación auricular. Estudio ESPARTA. Med. Clin. (Barc). 151, 8–15 (2018).
5.
Mostaza JM, Jiménez MJR, Laiglesia FJR et al. Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment. J. Geriatr. Cardiol. 15(4), 268–274 (2018).
6.
Krupenin P, Gabitova M, Bordovsky S et al. Impact of atrial fibrillation on the rate of mild cognitive impairment in the elderly. J. Neurol. Sci. 394, 75–77 (2018).
7.
Requena Calleja MA, Arenas Miquélez A, Díez-Manglano J et al. Sarcopenia, fragilidad, deterioro cognitivo y mortalidad en pacientes ancianos con fibrilación auricular no valvular. Rev. Clin. Esp. 219(8), 424–432 (2019).
8.
Shen NN, Zhang XM, Le KJ et al. Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: protocol for a systematic review and meta-analysis. Medicine (Baltimore). 98(26), e16194 (2019).
9.
Barrios V, Escobar C, Calderón A, Zamorano JL. Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain. Future Cardiol. 10(2), 215–220 (2014).
10.
Iñiguez Vázquez I, Monte Secades R, Matesanz Fernández M, Romay Lema EM, Rubal Bran D, Casariego Vales E. Características y patrón temporal de reingresos de los pacientes con fibrilación auricular hospitalizados en servicios médicos. Rev. Clin. Esp. 217, 309–314 (2017).
11.
Conde-Martel A, Arkuch ME. Fibrilación auricular, reingresos y comorbilidad. Rev. Clin. Esp. 217, 325–326 (2017).
12.
Burton DG, Allen MC, Bird JL, Faragher RG. Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. J. Pharm. Pharmacol. 57(6), 671–679 (2005).
13.
Schmucker DL. Age-related changes in liver structure and function: implications for disease? Exp. Gerontol. 40(8–9), 650–659 (2005).
14.
Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin. Drug. Metab. Toxicol. 11(4), 491–508 (2015).
15.
Chatap G, Giraud K, Vincent JP. Atrial fibrillation in the elderly: facts and management. Drugs Aging 19(11), 819–846 (2002).
16.
Karamichalakis N, Letsas KP, Vlachos K et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc. Health Risk Manag. 11, 555–562 (2015).
17.
Marini C, De Santis F, Sacco S et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36(6), 1115–1119 (2005).
18.
Mérida-Rodrigo L, Poveda-Gómez F, Camafort-Babkowski M et al. Supervivencia a largo plazo del ictus isquémico. Rev. Clin. Esp. 212, 223–228 (2012).
19.
Naderi S, Wang Y, Miller AL et al. The impact of age on the epidemiology of atrial fibrillation hospitalizations. Am. J. Med. 127(2), 158.e1–7 (2014).
20.
Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 37, 2893–2962 (2016).
21.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2), 263–272 (2010).
22.
Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J. Am. Coll. Cardiol. 56(11), 827–837 (2010).
23.
Kooistra HA, Calf AH, Piersma-Wichers M et al. Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists. JAMA Intern. Med. 176(8), 1176–1183 (2016).
24.
Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am. J. Med. 118, 612–617 (2005).
25.
Shinohara M, Fujino T, Yao S et al. Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation. J. Cardiol. 73(1), 7–13 (2018).
26.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5), 1093–1100 (2010).
27.
Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883–891 (2011).
• Rivaroxaban proved to be noninferior to warfarin for the prevention of stroke and systemic embolism. While no differences were recorded for major bleeding, intracranial and fatal bleeding were less common in the rivaroxaban group.
28.
Yamashita Y, Hamatani Y, Esato M et al. Clinical characteristics and outcomes in extreme elderly (age ≥85 years) Japanese patients with atrial fibrillation: the Fushimi AF registry. Chest 149(2), 401–412 (2016).
29.
Patti G, Lucerna M, Pecen L et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J. Am. Heart Assoc. 6(7), pii: e005657 (2017).
30.
Giustozzi M, Vedovati MC, Verso M et al. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: a multicentre observational study. Int. J. Cardiol. 281, 56–61 (2019).
•• DOACs seem to be a reasonable option for prevention of ischemic stroke, transient ischemic attack and systemic embolism in nonagenarians with atrial fibrillation (AF).
31.
Ekerstad N, Karlsson T, Söderqvist S, Karlson BW. Hospitalized frail elderly patients – atrial fibrillation, anticoagulation and 12 months' outcomes. Clin. Interv. Aging. 13, 749–756 (2018).
32.
Zeng D, Jiang C, Su C, Tan Y, Wu J. Anticoagulation in atrial fibrillation and cognitive decline: a systematic review and meta-analysis. Medicine (Baltimore). 98, e14499 (2019).
33.
Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke 46(1), 143–150 (2015).
34.
Potpara TS, Simovic S, Pavlovic N et al. Stroke prevention in elderly patients with non-valvular atrial fibrillation in the BALKAN-AF survey. Eur. J. Clin. Invest., e13200 (2020).
35.
Fumagalli S, Said SAM, Laroche C et al. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: the EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). JACC. Clin. Electrophysiol. 1(4), 326–334 (2015).
36.
Gullón A, Formiga F, Díez-Manglano J et al. Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation. Intern. Emerg. Med. 14(1), 59–69 (2019). Erratum in: Intern. Emerg. Med. 14, 335 (2019).
37.
Gullón A, Sánchez Fuentes D, López-de-Sá E et al. Uso de anticoagulantes orales en situaciones clínicas complejas con fibrilación auricular. Med. Clin (Barc). 150(Suppl. 1), 8–24 (2018).
38.
Lefebvre MC, St-Onge M, Glazer-Cavanagh M et al. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can. J. Cardiol. 32(2), 169–176 (2016).
39.
Díez-Manglano J, Mostaza JM, Pose A et al. Factors associated with discontinuing or not starting oral anticoagulant therapy in older hospitalized patients with non-valvular atrial fibrillation. Geriatr. Gerontol. Int. 18(8), 1219–1224 (2018).
40.
Blacher J, Sorbets E, Guedj Meynier D et al. Determinants of antithrombotic treatment for atrial fibrillation in octogenarians: results of the OCTOFA study. Clin. Drug Investig. 39(9), 891–898 (2019).
41.
Giorgi-Pierfranceschi M, Artom N, Di Pasquale G et al. Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation. Eur J. Prev. Cardiol. 26(6), 660–663 (2019).
42.
Fernández Domínguez MJ, Hernández Gómez MA, Garrido Barral A, González Moneo MJ. Haciendo equilibrios entre los riesgos y beneficios del tratamiento farmacológico en demencia, dolor crónico y anticoagulación en personas mayores. Aten. Primaria. 50(S2), 39–50 (2018).
43.
Hsu JC, Maddox TM, Kennedy KF et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol. 1(1), 55–62 (2016).
44.
Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age. Ageing 36(2), 151–156 (2007).
45.
Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370, 493–503 (2007).
46.
Bai Y, Guo SD, Deng H et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age. Ageing 47(1), 9–17 (2018).
47.
Suárez-Fernández C, Gullón A. El reto del tratamiento antitrombótico en ancianos con fibrilación auricular. ¿Justifica la edad la estrategia antitrombótica en ancianos con fibrilación auricular? Rev. Esp. Geriatr. Gerontol. 53, 317–318 (2018).
48.
Lafuente-Lafuente C, Oasi C, Belmin J. Treatment with oral anticoagulants in older patients: should warfarin still be prescribed? Presse Med. 48(2), 154–164 (2019).
49.
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139–1151 (2009).
50.
Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981–992 (2011).
51.
Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22), 2093–2104 (2013).
52.
Lauw MN, Eikelboom JW, Coppens M et al. Effects of dabigatran according to age in atrial fibrillation. Heart 103(13), 1015–1023 (2017).
53.
Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 130(2), 138–146 (2014).
•• A prespecified secondary analysis showed that elderly patients had higher stroke and major bleeding rates than younger patients. However, the safety and efficacy profile of rivaroxaban relative to warfarin, which did not differ with age, supports rivaroxaban as an alternative for elderly patients.
54.
Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur. Heart J. 35(28), 1864–1872 (2014).
•• The risk of stroke increases with age in patients with AF. The absolute benefits of apixaban were greater in elderly patients.
55.
Kato ET, Giugliano RP, Ruff CT et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J. Am. Heart Assoc. 5(5), pii: e003432 (2016).
•• In elderly patients with AF, treatment with edoxaban provides an even greater absolute reduction in safety events over warfarin than in younger patients.
56.
Renda G, di Nicola M, De Caterina R. Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in Phase III atrial fibrillation trials. Am. J. Med. 128(9), 1007–1014 (2015).
57.
Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J. Am. Geriatr. Soc. 62(5), 857–864 (2014).
58.
Lin L, Lim WS, Zhou HJ et al. Clinical and safety outcomes of oral antithrombotics for stroke prevention in atrial fibrillation: a systematic review and network meta-analysis. J. Am. Med. Dir. Assoc. 16(12), 1103.e1–19 (2015).
59.
Chao TF, Liu CJ, Lin YJ et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 138(1), 37–47 (2018).
60.
Steffel J, Giugliano RP, Braunwald E et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J. Am. Coll. Cardiol. 68(11), 1169–1178 (2016).
61.
Cheng W, Liu W, Li B, Li D. Relationship of anticoagulant therapy with cognitive impairment among patients with atrial fibrillation: a meta-analysis and systematic review. J. Cardiovasc. Pharmacol. 71(6), 380–387 (2018).
62.
Fauchier L, Blin P, Sacher F et al. Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study. Europace 22(2), 205–215 (2020).
63.
Wang KL, Lopes RD, Patel MR et al. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur. Heart J. 40(19), 1492–1500 (2019).
64.
Bando S, Nishikado A, Hiura N et al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J. Cardiol. 71(2), 197–201 (2018).
65.
Monelli M, Molteni M, Cassetti G et al. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA). Vasc. Health Risk Manag. 15, 19–25 (2019).
66.
Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 20(3), 420–428 (2018).
67.
Cerdá M, Cerezo-Manchado JJ, Johansson E et al. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. J. Comp. Eff. Res. 8(3), 165–178 (2019).
68.
Steinberg BA, Shrader P, Pieper K et al. Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J. Am. Heart Assoc. 7(4), pii: e007633 (2018).
69.
Ruiz Ortiz M, Muñiz J, Raña Míguez P et al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA registry. Europace 20(10), 1577–1583 (2018).
70.
Sato T, Aizawa Y, Fuse K et al. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry. J. Stroke. Cerebrovasc. Dis. 27(11), 3280–3288 (2018).
71.
Ablefoni K, Buchholz A, Ueberham L et al. Initial rivaroxaban dosing in patients with atrial fibrillation. Clin. Cardiol. 42(10), 873–880 (2019).
72.
Shimokawa H, Yamashita T, Uchiyama S et al. The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Int. J. Cardiol. 258, 126–132 (2018).
73.
Kirchhof P, Radaideh G, Kim YH et al. Global prospective safety analysis of rivaroxaban. J. Am. Coll. Cardiol. 72(2), 141–153 (2018).
74.
Andrade J, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can. J. Cardiol. 32(6), 747–753 (2016).
75.
Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 39(16), 1330–1393 (2018).
• The European Heart Rhythm Association guidelines attempt to unify information provided to physicians on the use of nonvitamin K antagonist oral anticoagulants.
76.
Sato T, Aizawa Y, Fuse K et al. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry. J. Stroke Cerebrovasc. Dis. 27(11), 3280–3288 (2018).
77.
Jacobs MS, van Hulst M, Campmans Z, Tieleman RG. Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. Neth. Heart J. 27(7–8), 371–377 (2019).
78.
Xing LY, Barcella CA, Sindet-Pedersen C, Bonde AN, Gislason GH, Olesen JB. Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a Danish nationwide cohort study. Thromb. Res. 178, 101–109 (2019).
79.
Lee SR, Lee YS, Park JS et al. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation. Yonsei Med. J. 60(3), 277–284 (2019).
80.
Steinberg BA, Shrader P, Thomas L et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes. J. Am. Coll. Cardiol. 68(24), 2597–2604 (2016).
81.
Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 353, i3189 (2016).
82.
Nielsen PB, Skjoth F, Sogaard M, Kjaldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356, j510 (2017).
83.
Escobar C, Martí-Almor J, Pérez Cabeza A, Martínez-Zapata MJ. Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis. Rev. Esp. Cardiol. 72, 305–316 (2019).
84.
Arbel R, Sergienko R, Hammerman A et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am. J. Med. 132(7), 847–855 (2019).
85.
Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J. Am. Coll. Cardiol. 69(23), 2779–2790 (2017).
86.
Ruiz Ortiz M, Esteve-Pastor MA, Roldán I, Muñiz J, Marín F, Anguita M. Impacto pronóstico de las dosis inapropiadas de anticoagulantes de acción directa en la práctica clínica diaria. Rev Esp Cardiol. 73(4), 329–330 (2020).
87.
Alnsasra H, Haim M, Senderey AB et al. Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: experience from the real world. Heart Rhythm. 16(1), 31–37 (2019).
88.
January CT, Wann LS, Calkins H et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 140(2), e125–e151 (2019).
89.
January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130(23), e199–e267 (2014).
90.
Contreras Muruaga MM, Reig G, Vivancos J et al. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN. Rev. Clin. Esp. 218(7), 327–335 (2018).
91.
Batalla Insenser B, Pertierra Uriel U, Sánchez Biosca A, Sobrino Martínez J. Control de la anticoagulación en pacientes hospitalizados con fibrilación auricular no valvular en tratamiento crónico con anticoagulantes orales. Rev. Clin. Esp. 218, 267–269 (2018).
92.
Kim D, Yang PS, Jang E et al. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Europace 22(4), 547–557 (2020).
93.
Lip GYH, Banerjee A, Boriani G et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 154(5), 1121–1201 (2018).
94.
NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger D, Amerena J, Attia J et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart. Lung. Circ. 27(10), 1209–1266 (2018).
95.
Andrade JG, Verma A, Mitchell LB et al. 2018 Focused Update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can. J. Cardiol. 34(11), 1371–1392 (2018).
96.
Joung B, Lee JM, Lee KH et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ. J. 48(12), 1033–1080 (2018).
97.
Chiang CE, Okumura K, Zhang S et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J. Arrhythm. 33(4), 345–367 (2017).
98.
Formiga F, Gullón A, Suárez-Fernández C. Frailty should not be a justification for not prescribing anticoagulation in older patients with atrial fibrillation. J. Am. Med. Dir. Assoc. 20(6), 786–787 (2019).
Information & Authors
Information
Published In
Pages: 509 - 523
PubMed: 32329353
Copyright
© 2020 Carmen Suárez Fernández et al. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 17 December 2019
Accepted: 28 February 2020
Published online: 24 April 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0197
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- E.M. Bacas, J.C.P. Cuenca, L.L. Gata, M.M. Acevedo, A.F. García, I.C. Naranjo, Frequency of and factors associated with underdosing of direct oral anticoagulants in patients with ischaemic stroke and atrial fibrillation, Neurology Perspectives, 10.1016/j.neurop.2024.100160, 4, 3, (100160), (2024).
- Elkholy Emad, Elshammaa Khaled, Bajnaid Eshtyag, Aboul-Enein Fatima, Shalaby Ghada, Role of Clinical Pharmacy anticoagulation service on Apixaban prescribing appropriateness in atrial fibrillation in Saudi Arabia, Current Problems in Cardiology, 10.1016/j.cpcardiol.2024.102517, 49, 6, (102517), (2024).
- Esther Vanderstuyft, Julie Hias, Laura Hellemans, Lucas Van Aelst, Jos Tournoy, Lorenz Roger Van der Linden, Appropriateness of antithrombotics in geriatric inpatients with atrial fibrillation: a retrospective, cross-sectional study, European Journal of Hospital Pharmacy, 10.1136/ejhpharm-2023-004033, 32, 6, (514-521), (2024).
- João Presume, Jorge Ferreira, Regina Ribeiras, Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy, Cardiology and Therapy, 10.1007/s40119-024-00352-x, 13, 1, (1-16), (2024).
- Larysa A. Vozniuk, Olga V. Dzekan, Sergii O. Siromakha, Non-Vitamin K Antagonist Oral Anticoagulants in Differentiated Approach to the Use in Cardiological Practice: Literature Review, Ukrainian Journal of Cardiovascular Surgery, 10.30702/ujcvs/23.31(03)/VD041-111126, 31, 3, (111-126), (2023).
- Karen Lipworth, Improving the Effectiveness of Anticoagulant Therapy: The Promise of Factor XI Inhibition, European Medical Journal, 10.33590/emj/10308910, (18-29), (2023).
- John W. Eikelboom, Jeffrey I. Weitz, Direct Oral Anticoagulants in the Very Elderly, Thrombosis and Haemostasis, 10.1055/a-2021-8910, 123, 04, (377-379), (2023).
- Claudiu Morgovan, Carmen Maximiliana Dobrea, Adriana Aurelia Chis, Anca Maria Juncan, Anca Maria Arseniu, Luca Liviu Rus, Felicia Gabriela Gligor, Simona Alexandrina Ardelean, Laurentiu Stoicescu, Steliana Ghibu, Adina Frum, A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database, Pharmaceuticals, 10.3390/ph16030455, 16, 3, (455), (2023).
- Maria Giner-Soriano, Oriol Prat-Vallverdú, Dan Ouchi, Carles Vilaplana-Carnerero, Rosa Morros, Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in catalonia, Frontiers in Pharmacology, 10.3389/fphar.2023.1110036, 14, (2023).
- Vivencio Barrios, Sergio Cinza-Sanjurjo, Javier García-Alegría, Román Freixa-Pamias, Frederic Llordachs-Marques, Carlos A Molina, Amparo Santamaría, David Vivas, Carmen Suárez Fernandez, Role of Telemedicine in the Management of Oral Anticoagulation in Atrial Fibrillation: A Practical Clinical Approach, Future Cardiology, 10.2217/fca-2022-0044, 18, 9, (743-754), (2022).